ZNF71 KRAB in NSCLC: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Nancy Lan Guo.

Lung cancer is the second most common cancer and remains the leading cause of cancer-related mortality in the U.S. Non-small-cell lung cancer (NSCLC) accounts for 84% of lung cancer cases. Our previous study found that zinc finger protein 71 (ZNF71) mRNA expression was associated with chemosensitivity and its protein expression was prognostic of non-small-cell lung cancer (NSCLC). 

  • KRAB isoform
  • zinc finger protein
  • EMT
  • prognosis
  • chemoresponse
  • proliferation
  • CRISPR-Cas9
  • RNAi
Please wait, diff process is still running!

References

  1. Lung Cancer-Non-Small Cell: Statistics. Available online: and (accessed on 2 October 2020).
  2. Hoffman, P.C.; Mauer, A.M.; Vokes, E.E. Lung cancer. Lancet 2000, 355, 479–485.
  3. Zheng, Y.; Jaklitsch, M.T.; Bueno, R. Neoadjuvant Therapy in Non-Small Cell Lung Cancer. Surg. Oncol. Clin. North Am. 2016, 25, 567–584.
  4. Crinò, L.; Weder, W.; Van Meerbeeck, J.; Felip, E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21, v103–v115.
  5. Byron, E.; Pinder-Schenck, M. Systemic and targeted therapies for early-stage lung cancer. Cancer Control. 2014, 21, 21–31.
  6. Guo, N.L.; Dowlati, A.; Raese, R.A.; Dong, C.; Chen, G.; Beer, D.G.; Shaffer, J.; Singh, S.; Bokhary, U.; Liu, L.; et al. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine 2018, 32, 102–110.
  7. Laity, J.H.; Lee, B.M.; Wright, P.E. Zinc finger proteins: New insights into structural and functional diversity. Curr. Opin. Struct. Biol. 2001, 11, 39–46.
  8. Cassandri, M.; Smirnov, A.; Novelli, F.; Pitolli, C.; Agostini, M.; Malewicz, M.; Melino, G.; Raschellà, G. Zinc-finger proteins in health and disease. Cell Death Discov. 2017, 3, 17071.
  9. Huntley, S.; Baggott, D.M.; Hamilton, A.T.; Tran-Gyamfi, M.; Yang, S.; Kim, J.; Gordon, L.; Branscomb, E.; Stubbs, L. A comprehensive catalog of human KRAB-associated zinc finger genes: Insights into the evolutionary history of a large family of transcriptional repressors. Genome Res. 2006, 16, 669–677.
  10. Bruno, M.; Mahgoub, M.; Macfarlan, T.S. The Arms Race Between KRAB-Zinc Finger Proteins and Endogenous Retroelements and Its Impact on Mammals. Annu. Rev. Genet. 2019, 53, 393–416.
  11. Ecco, G.; Imbeault, M.; Trono, D. KRAB zinc finger proteins. Development 2017, 144, 2719–2729.
  12. Lupo, A.; Cesaro, E.; Montano, G.; Zurlo, D.; Izzo, P.; Costanzo, P. KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions. Curr. Genom. 2013, 14, 268–278.
  13. Murakami, T.; Mataki, C.; Nagao, C.; Umetani, M.; Wada, Y.; Ishii, M.; Tsutsumi, S.; Kohro, T.; Saiura, A.; Aburatani, H.; et al. The Gene Expression Profile of Human Umbilical Vein Endothelial Cells Stimulated by Tumor Necrosis Factor a using DNA Microarray Analysis. J. Atheroscler. Thromb. 2000, 7, 39–44.
  14. Kim, J.-H.; Cheong, H.S.; Park, J.S.; Jang, A.-S.; Uh, S.-T.; Kim, Y.-H.; Kim, M.-K.; Choi, I.S.; Cho, S.H.; Choi, B.W.; et al. A Genome-Wide Association Study of Total Serum and Mite-Specific IgEs in Asthma Patients. PLoS ONE 2013, 8, e71958.
  15. Roche, J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers 2018, 10, 52.
  16. Nieto, M.A.; Huang, R.Y.-J.; Jackson, R.A.; Thiery, J.P. EMT: 2016. Cell 2016, 166, 21–45.
  17. Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging Biological Principles of Metastasis. Cell 2017, 168, 670–691.
  18. Moustakas, A.; De Herreros, A.G. Epithelial-mesenchymal transition in cancer. Mol. Oncol. 2017, 11, 715–717.
  19. Block, C.J.; Dyson, G.; Campeanu, I.J.; Watza, D.; Ratnam, M.; Wu, G. A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer. Sci. Rep. 2019, 9, 1–14.
  20. Yoshihara, K.; Shahmoradgoli, M.; Martínez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Treviño, V.; Shen, H.; Laird, P.W.; Levine, D.A.; et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013, 4, 2612.
  21. Panchy, N.; Azeredo-Tseng, C.; Luo, M.; Randall, N.; Hong, T. Integrative Transcriptomic Analysis Reveals a Multiphasic Epithelial-Mesenchymal Spectrum in Cancer and Non-tumorigenic Cells. Front. Oncol. 2020, 9, 1479.
  22. Friedman, J.R.; Fredericks, W.J.E.; Jensen, D.; Speicher, D.W.; Huang, X.P.; Neilson, E.G.; Rauscher, F.J. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996, 10, 2067–2078.
  23. Chen, L.; Munoz-Antonia, T.; Cress, W.D. Trim28 Contributes to EMT via Regulation of E-Cadherin and N-Cadherin in Lung Cancer Cell Lines. PLoS ONE 2014, 9, e101040.
  24. Pei, L.; He, X.; Li, S.; Sun, R.; Xiang, Q.; Ren, G.; Xiang, T. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor but is silenced by CpG methylation in gastric cancer. Int. J. Oncol. 2018, 53, 961–972.
  25. Mezheyeuski, A.; Bergsland, C.H.; Backman, M.; Djureinovic, D.; Sjöblom, T.; Bruun, J.; Micke, P. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. J. Pathol. 2018, 244, 421–431.
  26. Broad Institute. DepMap 20Q2 Public. In DepMap; Broad Institute: Cambridge, MA, USA, 2020.
  27. Meyers, R.M.; Bryan, J.G.; McFarland, J.M.; Weir, B.A.; Sizemore, A.E.; Xu, H.; Dharia, N.V.; Montgomery, P.G.; Cowley, G.S.; Pantel, S.; et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 2017, 49, 1779–1784.
  28. McFarland, J.M.; Ho, Z.V.; Kugener, G.; Dempster, J.M.; Montgomery, P.G.; Bryan, J.G.; Krill-Burger, J.M.; Green, T.M.; Vazquez, F.; Boehm, J.S.; et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat. Commun. 2018, 9, 1–13.
  29. Carnio, S.; Novello, S.; Papotti, M.; Iacono, M.L.; Scagliotti, G.V. Prognostic and predictive biomarkers in early stage non-small cell lung cancer: Tumor based approaches including gene signatures. Transl. Lung Cancer Res. 2013, 2, 372–381.
  30. Kosaka, T.; Yatabe, Y.; Onozato, R.; Kuwano, H.; Mitsudomi, T. Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. J. Thorac. Oncol. 2009, 4, 22–29.
  31. Pécuchet, N.; Laurent-Puig, P.; Mansuet-Lupo, A.; Legras, A.; Alifano, M.; Pallier, K.; Didelot, A.; Gibault, L.; Danel, C.; Just, P.-A.; et al. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget 2015, 8, 23831–23840.
  32. Lord, R.V.N.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sánchez, J.M.; Gumerlock, P.H.; Tarón, M.; et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8, 2286–2291.
  33. Simon, G.R.; Sharma, S.; Cantor, A.; Smith, P.; Bepler, G. ERCC1 Expression Is a Predictor of Survival in Resected Patients with Non-small Cell Lung Cancer. Chest 2005, 127, 978–983.
  34. Zhu, C.-Q.; Ding, K.; Strumpf, D.; Weir, B.A.; Meyerson, M.; Pennell, N.; Thomas, R.K.; Naoki, K.; Ladd-Acosta, C.; Liu, N.; et al. Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2010, 28, 4417–4424.
  35. Chen, D.-T.; Hsu, Y.-L.; Fulp, W.J.; Coppola, D.; Haura, E.B.; Yeatman, T.J.; Cress, W.D. Prognostic and Predictive Value of a Malignancy-Risk Gene Signature in Early-Stage Non-Small Cell Lung Cancer. J. Natl. Cancer Inst. 2011, 103, 1859–1870.
  36. Kratz, J.R.; He, J.; Eeden, S.K.V.D.; Zhu, Z.-H.; Gao, W.; Pham, P.T.; Mulvihill, M.S.; Ziaei, F.; Zhang, H.; Su, B.; et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies. Lancet 2012, 379, 823–832.
  37. Tang, H.; Xiao, G.; Behrens, C.; Schiller, J.; Allen, J.; Chow, C.-W.; Suraokar, M.; Corvalan, A.; Mao, J.; White, M.A.; et al. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients. Clin. Cancer Res. 2013, 19, 1577–1586.
  38. Woodard, G.A.; Wang, S.X.; Kratz, J.R.; Zoon-Besselink, C.T.; Chiang, C.-Y.; Gubens, M.A.; Jahan, T.M.; Blakely, C.M.; Jones, K.D.; Mann, M.J.; et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin. Lung Cancer 2018, 19, 58–64.
  39. Houston, K.A.; Henley, S.J.; Li, J.; White, M.C.; Richards, T.B. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. Lung Cancer 2014, 86, 22–28.
  40. Zheng, Y.; Bueno, R. Commercially available prognostic molecular models in early-stage lung cancer: A review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests. Expert Rev. Mol. Diagn. 2015, 15, 589–596.
  41. Myriad. All Products. Available online: (accessed on 31 December 2020).
  42. Klug, A. The Discovery of Zinc Fingers and Their Applications in Gene Regulation and Genome Manipulation. Annu. Rev. Biochem. 2010, 79, 213–231.
  43. Yang, P.; Wang, Y.; Macfarlan, T.S. The Role of KRAB-ZFPs in Transposable Element Repression and Mammalian Evolution. Trends Genet. 2017, 33, 871–881.
  44. Addison, J.B.; Koontz, C.; Fugett, J.H.; Creighton, C.J.; Chen, N.; Farrugia, M.K.; Padon, R.R.; Voronkova, M.A.; McLaughlin, S.L.; Livengood, R.H.; et al. KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res. 2014, 75, 344–355.
  45. Ho, J.; Kong, J.-W.-F.; Choong, L.-Y.; Loh, M.-C.-S.; Toy, W.; Chong, P.-K.; Wong, C.-H.; Wong, C.-Y.; Shah, N.; Lim, Y.-P. Novel Breast Cancer Metastasis-Associated Proteins. J. Proteome Res. 2009, 8, 583–594.
  46. Zhang, X.; Jiang, G.; Wu, J.; Zhou, H.; Zhang, Y.; Miao, Y.; Feng, Y.; Yu, J. Zinc finger protein 668 suppresses non-small cell lung cancer invasion and migration by downregulating Snail and upregulating E-cadherin and zonula occludens-1. Oncol. Lett. 2018, 15, 3806–3813.
  47. Tulchinsky, E.; Demidov, O.; Kriajevska, M.; Barlev, N.A.; Imyanitov, E. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim. Biophys. Acta (BBA) Bioenerg. 2019, 1871, 29–39.
  48. Warzecha, C.C.; Carstens, R.P. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin. Cancer Biol. 2012, 22, 417–427.
  49. Li, J.; Choi, P.S.; Chaffer, C.L.; Labella, K.; Hwang, J.H.O.; Giacomelli, A.; Kim, J.W.; Ilic, N.; Doench, J.G.; Ly, S.H.; et al. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife 2018, 7.
  50. Chen, L.; Chen, D.-T.; Kurtyka, C.; Rawal, B.; Fulp, W.J.; Haura, E.B.; Cress, W. Tripartite Motif Containing 28 (Trim28) Can Regulate Cell Proliferation by Bridging HDAC1/E2F Interactions. J. Biol. Chem. 2012, 287, 40106–40118.
  51. Czerwińska, P.; Mazurek, S.; Wiznerowicz, M. The complexity of TRIM28 contribution to cancer. J. Biomed. Sci. 2017, 24, 1–14.
  52. Arrieta, O.; Barrón, F.; Ramírez-Tirado, L.A.; Zatarain-Barrón, Z.L.; Cardona, A.F.; Díaz-García, D.; Yamamoto Ramos, M.; Mota-Vega, B.; Carmona, A.; Peralta Álvarez, M.P.; et al. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020, 6, 856–864.
  53. Sobocińska, J.; Molenda, S.; Machnik, M.; Oleksiewicz, U. KRAB-ZFP Transcriptional Regulators Acting as Oncogenes and Tumor Suppressors: An Overview. Int. J. Mol. Sci. 2021, 22, 2212.
  54. Huang, C.; Jia, Y.; Yang, S.; Chen, B.; Sun, H.; Shen, F.; Wang, Y. Characterization of ZNF23, a KRAB-containing protein that is downregulated in human cancers and inhibits cell cycle progression. Exp. Cell Res. 2007, 313, 254–263.
  55. He, B.; Wang, B.; Wang, H.; Zhang, C.; Wu, Y.; Fu, L.; Yu, G. RBAK is upregulated in non-small cell lung cancer and promotes cell migration and invasion. Exp. Ther. Med. 2019, 18, 2942–2948.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback